AI-generated analysis. Always verify with the original filing.
Humacyte, Inc. disclosed preliminary financial information for the year ended December 31, 2025, estimating $50.9 million in cash, cash equivalents and restricted cash, $2.0 million in total revenue including $1.4 million in product revenue, and 61 unit sales of Symvess. The company suspended and terminated its ATM prospectus for up to $60 million of common stock and provided commercial and regulatory updates including a $1.48 million purchase commitment in KSA and an MAA filing in Israel.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. The disclosure set forth under the caption "Operational Updates--Preliminary Financial Information for the Year
, below, is incorporated herein by reference. Item 8.01. Other Events. Suspension and Termination of ATM Prospectus On March 19, 2026, Humacyte, Inc. (the “Comp
. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Humacyte, Inc. Investor Presentation March 2026. 99.2 Risk Factor Updates, da
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $2.00 | |
| Product Revenue | $1.40 |